Clinical Trial Update: A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL) [Phase 3]

View source ↗

Summary

Phase 3 trial assessing efficacy and safety of patiromer for treating hyperkalemia in chronic kidney disease; study completed with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperkalemia

Drugs mentioned

• Patiromer (patiromer)

Snippet

Sponsor: Relypsa, Inc. | Conditions: Chronic Kidney Disease (CKD), Hyperkalemia (HK) | Phase 3 | Status: COMPLETED | Results posted: 2015-12-15